Jenkins / Toth / Lyons Lipoproteins in Diabetes Mellitus
1. Auflage 2014
ISBN: 978-1-4614-7554-5
Verlag: Springer US
Format: PDF
Kopierschutz: 1 - PDF Watermark
E-Book, Englisch, 466 Seiten, eBook
Reihe: Contemporary Diabetes
ISBN: 978-1-4614-7554-5
Verlag: Springer US
Format: PDF
Kopierschutz: 1 - PDF Watermark
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Weitere Infos & Material
Laboratory Assessment of Lipoproteins in Diabetes.- Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin Resistance Diabetes.- Insulin Resistance and Atherosclerosis.- Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism in the Setting of Type 2 Diabetes.- Lipoprotein Metabolism and Alterations induced by insulin resistance and diabetes.- Production and Metabolism of Triglyceride-Rich Lipoproteins in both the Normal and Diabetic States.- Lipoprotein(a): Structure, Metabolism and Pathophysiology.- Lipoprotein Glycation in Diabetes Mellitus.-Lipoprotein (LDL and HDL) Oxidation in Diabetes Mellitus.- The Role of Modified Forms of LDL and Corresponding Autoantibodies in the Development of Complications in Diabetes.- Lipid – Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of Diabetes.- Tools for Assessing Lipoprotein Metabolism in Diabetes Mellitus.- Endothelial Dysfunction and Dyslipidaemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy.- Lipoproteins and Diabetic Nephropathy.- Roles of Extravasated and Modified Plasma Lipoproteins in Diabetic Retinopathy.- Effects of Lifestyle (Diet, Plant Sterols, Excercise) and Glycemic Control on Lipoporteins in Diabetes.- About Randomised Clinical Trials Related to Lipoproteins in Diabetes Mellitus.- Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients.- The PPAR System in Diabetes.- Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients.- Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients.- Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding Resins (Colesevelam HCl) as Therapy for Dyslipidemia in Patients with Diabetes Mellitus.- Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes.